Clinical Trial Update: Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating intravenous TAD 600 mg/4 mL solution for injection to prevent myocardial injury in patients with pneumonia is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Injury
• Pneumonia

Drugs mentioned

• TAD 600 Mg/4 ML Solution for Injection

Snippet

Sponsor: Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica | Conditions: Pneumonia, Myocardial Injury | Phase 3 | Status: RECRUITING